AssetMark’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.46K Buy
370
+25
+7% +$671 ﹤0.01% 2620
2026
Q2
$8.73K Buy
345
+100
+41% +$2.2K ﹤0.01% 2503
2026
Q1
$5.45K Buy
245
+23
+10% +$550 ﹤0.01% 2531
2025
Q4
$5.93K Buy
222
+25
+13% +$597 ﹤0.01% 2409
2025
Q3
$4.2K Buy
197
+169
+604% +$4K ﹤0.01% 2401
2025
Q2
$604 Sell
28
-9
-24% -$167 ﹤0.01% 2711
2025
Q1
$615 Hold
37
– – ﹤0.01% 2378
2024
Q4
$679 Buy
+37
New +$597 ﹤0.01% 2325
2016
Q1
– Sell
-15
Closed -$1K – 1163
2015
Q4
$1K Buy
+15
New +$528 ﹤0.01% 1156

Other funds holding ACAD

AssetMark's ACAD Position: Q3 2026 in Review

AssetMark increased its Acadia Pharmaceuticals (ACAD) stake by 7.2% in Q3 2026, buying an estimated $671 and bringing the position to 370 shares worth $7.46K. The position accounts for ﹤0.01% of the portfolio, ranked #2620.

AssetMark first reported a position in ACAD in Q4 2015 and has held it in 9 quarters since. The position peaked at $8.73K in Q2 2026. 268 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • AssetMark held 370 shares of Acadia Pharmaceuticals worth $7.46K as of Q3 2026.
  • AssetMark bought 25 Acadia Pharmaceuticals shares in Q3 2026, an estimated $671.
  • Acadia Pharmaceuticals made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2620 holding.
  • AssetMark first reported a position in Acadia Pharmaceuticals in Q4 2015 and has held it in 9 quarters since.
  • AssetMark's Acadia Pharmaceuticals position peaked at $8.73K in Q2 2026.
  • 268 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.